Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Nerve Growth Factor for Acute Ischemic Stroke
NCT03686163Phase 4Completed
- Sponsor
- Jinling Hospital
- Start
- Jan 2016
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Nerve growth factor in ischemic stroke (2 arms), sponsored by Jinling Hospital. Primary endpoint: Favorable neurological function at 90 days. Started Jan 2016; status: completed.
02
Drugs
Nerve growth factor
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03686163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686163.